Literature DB >> 9583068

Systemic lupus erythematosus and pregnancy.

M Reichlin1.   

Abstract

Systemic lupus erythematosus (SLE) may improve, exacerbate or be unchanged during pregnancy. The activity of SLE at the time of conception has a major influence on pregnancy outcome: SLE patients with quiescent disease do well, while those with active, uncontrollable disease have a high abortion rate. There are specific autoantibodies that confer a high risk of abortion (e.g., IgG antiphospholipid antibodies). There are others, such as anti-Ro/SSA and anti-La/SSB, which confer a risk for neonatal lupus that includes lupus dermatitis, congenital complete heart block, thrombocytopenia and cholestatic jaundice, in order of their relative frequencies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9583068

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  2 in total

1.  Neo-epitopes are required for immunogenicity of the La/SS-B nuclear antigen in the context of late apoptotic cells.

Authors:  Z-J Pan; K Davis; S Maier; M P Bachmann; X R Kim-Howard; C Keech; T P Gordon; J McCluskey; A D Farris
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

2.  Maternal and fetal outcomes of 72 pregnancies in Argentine patients with systemic lupus erythematosus (SLE).

Authors:  Javier A Cavallasca; Hugo A Laborde; Hilda Ruda-Vega; Gustavo G Nasswetter
Journal:  Clin Rheumatol       Date:  2007-05-22       Impact factor: 3.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.